File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB)

TitleCharacterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB)
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2015
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl.1, p. S39, abstract no. 1149 How to Cite?
AbstractAIM: In study GS-US-174-0149, finite treatment for CHB with (TDF + PEG) 9 48 weeks increases rates of HBsAg loss at week 48 compared to TDF or PEG monotherapy (Kaplan–Meier estimate: 7.5, 0, and 2.4 %, respectively). Quantitative HBsAg data were analyzed to understand on-treatment HBsAg decline by treatment arm. METHODS: 740 patients with non-cirrhotic CHB were randomized 1: 1:1: 1 to (TDF + PEG) 9 48 weeks (Arm A); (TDF + PEG) 9 16 weeks followed by TDF 9 32 weeks (Arm B); continuous TDF (Arm C); PEG 9 48 weeks (Arm D). Quantitative HBsAg levels at baseline and on-treatment were analyzed and compared using Fisher’s or Wilcoxon tests. RESULTS: At baseline, for Arms A-D, respectively, 0.5 %, 1.6 %, 0 %, 1.1 % had HBsAg levels\10 IU/ml (p[0.05). By week 24, 11.1, 4.0, 0.6 and 5.8 % had HBsAg levels\10 IU/ml for Arms A-D, respectively (P\0.05). At Week 48, 15.8, 3.1, 1.2 and 11.3 % achieved HBsAg levels\10 IU/ml for Arms A-D, respectively (P\0.05); though there was no difference between Arms A vs. D (P = 0.26). Significant on-treatment reductions from baseline in HBsAg were seen at Week 48 in Arms A versus D (mean HBsAg change from baseline, -1.1 log10 IU/ml and -0.8 log10 IU/ml, respectively, P\0.05). CONCLUSION: PEG monotherapy and (TDF + PEG) 9 48 weeks resulted in significant on-treatment HBsAg reductions. Despite achieving similar percentages of on-treatment HBsAg\10 IU/mL, patients on TDF + PEG combination therapy for 48 weeks achieved higher rates of HBsAg loss and more profound drop in HBsAg titers than PEG monotherapy at week 48.
DescriptionConference Theme: New Horizons from East to west in Hepatology
Topic 10 - Hepatitis B: no. 1149
This journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey
Persistent Identifierhttp://hdl.handle.net/10722/214125
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorChan, HLY-
dc.contributor.authorKadayifci, A-
dc.contributor.authorPapatheodoridis, G-
dc.contributor.authorYuen, MF-
dc.contributor.authorChien, RN-
dc.contributor.authorKwan, WCP-
dc.contributor.authorLin, L-
dc.contributor.authorDinh, P-
dc.contributor.authorMartins, EB-
dc.contributor.authorCharuworn, P-
dc.contributor.authorSubramanian, GM-
dc.contributor.authorMchutchison, JG-
dc.contributor.authorPetersen, J-
dc.contributor.authorShiffman, M-
dc.contributor.authorReesink, HW-
dc.contributor.authorLim, SG-
dc.contributor.authorLim, YS-
dc.contributor.authorMarcellin, P-
dc.date.accessioned2015-08-21T02:27:32Z-
dc.date.available2015-08-21T02:27:32Z-
dc.date.issued2015-
dc.identifier.citationThe 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl.1, p. S39, abstract no. 1149-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/214125-
dc.descriptionConference Theme: New Horizons from East to west in Hepatology-
dc.descriptionTopic 10 - Hepatitis B: no. 1149-
dc.descriptionThis journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey-
dc.description.abstractAIM: In study GS-US-174-0149, finite treatment for CHB with (TDF + PEG) 9 48 weeks increases rates of HBsAg loss at week 48 compared to TDF or PEG monotherapy (Kaplan–Meier estimate: 7.5, 0, and 2.4 %, respectively). Quantitative HBsAg data were analyzed to understand on-treatment HBsAg decline by treatment arm. METHODS: 740 patients with non-cirrhotic CHB were randomized 1: 1:1: 1 to (TDF + PEG) 9 48 weeks (Arm A); (TDF + PEG) 9 16 weeks followed by TDF 9 32 weeks (Arm B); continuous TDF (Arm C); PEG 9 48 weeks (Arm D). Quantitative HBsAg levels at baseline and on-treatment were analyzed and compared using Fisher’s or Wilcoxon tests. RESULTS: At baseline, for Arms A-D, respectively, 0.5 %, 1.6 %, 0 %, 1.1 % had HBsAg levels\10 IU/ml (p[0.05). By week 24, 11.1, 4.0, 0.6 and 5.8 % had HBsAg levels\10 IU/ml for Arms A-D, respectively (P\0.05). At Week 48, 15.8, 3.1, 1.2 and 11.3 % achieved HBsAg levels\10 IU/ml for Arms A-D, respectively (P\0.05); though there was no difference between Arms A vs. D (P = 0.26). Significant on-treatment reductions from baseline in HBsAg were seen at Week 48 in Arms A versus D (mean HBsAg change from baseline, -1.1 log10 IU/ml and -0.8 log10 IU/ml, respectively, P\0.05). CONCLUSION: PEG monotherapy and (TDF + PEG) 9 48 weeks resulted in significant on-treatment HBsAg reductions. Despite achieving similar percentages of on-treatment HBsAg\10 IU/mL, patients on TDF + PEG combination therapy for 48 weeks achieved higher rates of HBsAg loss and more profound drop in HBsAg titers than PEG monotherapy at week 48.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s12072-015-9609-1-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleCharacterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB)-
dc.typeConference_Paper-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.doi10.1007/s12072-015-9609-1-
dc.identifier.hkuros248040-
dc.identifier.volume9-
dc.identifier.issuesuppl.1-
dc.identifier.spageS39, abstract no. 1149-
dc.identifier.epageS39, abstract no. 1149-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats